Oppenheimer downgraded Bioceres (BIOX) to Perform from Outperform without a price target The firm believes the company’s portfolio recapitalization “now appears incrementally challenging.” Bioceres is seeing pressure amid Argentina liquidity concerns, and the notice of default from one its largest stakeholders “creates a significant impediment to our portfolio transformation thesis,” the analyst tells investors in a research note. Oppenheimer cites Argentina volatility for the downgrade.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
- Bioceres Crop Solutions Faces Board Resignation Amid Financial Dispute
- Bioceres, Colorado Wheat Research Foundation team on HB4 wheat commercialization
- Bioceres price target lowered to $5 from $8 at Lake Street
- Bioceres downgraded to Hold from Buy at Canaccord
- Bioceres Crop Solutions: Hold Rating Amid Macroeconomic Challenges and Strategic Shift